- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02495662
The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT)
September 17, 2018 updated by: JorisRotmans, Leiden University Medical Center
This study will investigate if liposomal prednisolone is effective in promoting arteriovenous fistula (AVF) maturation when administered to human subjects after surgical creation of a radio-cephalic AVF.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
AVFs are the preferred means of vascular access for maintenance hemodialysis.
Nonmaturation occurs in 30-50% of cases, with highest rates in radio-cephalic fistulas.
Inflammatory cytokines are involved in this process of nonmaturation.
By suppressing inflammation, corticosteroids might promote maturation, but have significant systemic side effects.
Liposomal prednisolone has a long circulation time and targets inflamed tissue with low systemic concentrations and limited side effects.
In an animal study, it was demonstrated to promote AVF maturation.
At present, no drug therapy aimed at improving shunt maturation is available.
This study will investigate if liposomal prednisolone is effective in promoting AVF maturation when administered to human subjects after surgical creation of a radio-cephalic AVF.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zuid Holland
-
Leiden, Zuid Holland, Netherlands, 2333 ZA
- Leiden University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who are scheduled for creation of a radiocephalic AVF for maintenance hemodialysis.
- Male or female ≥ 18 years old.
- Patients are able and willing to give written informed consent.
Exclusion Criteria:
- Any concurrent illness, disability or clinically significant abnormality that may, as judged by the investigator, affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.
- Current participation in another interventional clinical trial or subjects who have received an investigational drug within 30 days prior to the baseline visit.
- History of psychosis.
- History of osteonecrosis
- Previous AVF in the ipsilateral arm.
- Current central venous catheter at the ipsilateral side.
- Treatment with oral, rectal or injectable (including intra-articular) glucocorticoids (CS) within 6 weeks prior to baseline visit. Inhaled glucocorticoids are allowed. Topical steroids are allowed, however subjects should not have received more than 100 gram of a mild to moderate topical corticosteroid cream per week, 50 gram of a potent corticosteroid cream per week or 30 gram of a very potent topical corticosteroid cream per week in the 4 weeks prior to the baseline visit.
- Treatment with immunosuppressant drugs. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs).
- Patients who are unlikely to adequately comply with the trial's procedures (due for instance to medical conditions likely to require an extended interruption or discontinuation, history of substance abuse or noncompliance).
- Women who are lactating, pregnant (positive pregnancy test at baseline) or planning to become pregnant during the course of the study.
- Unwillingness to use reliable and acceptable contraceptive methods throughout the study and till 3 months after last study medication except for female patients who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or at least 1 year postmenopausal.
- Malignant disease, unless cured. Current prostate carcinoma without current or planned cytostatic therapy is allowed.
- Uncontrolled Diabetes mellitus.
- Signs of active infection, requiring systemic treatment.
- Positive Quantiferon test.
- Subject with positive hepatitis panel (including hepatitis B surface antigen [HBsAg], and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody [anti-HCV]).
- History of anaphylaxis or severe allergic responses, including to radio-contrast agents.
- Planned live-virus vaccinations.
- Planned surgical interventions or planned elective hospital admissions within 6 weeks after AVF surgery. Planned hemodialysis sessions do not count as an exclusion criterion.
- Abnormal hepatic function (Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) or bilirubin > 2 x upper limit of normal) at the time of the screening visit.
- Clinically significant out-of-range values on hematology panel, at discretion of the Principal Investigator.
- Current substance abuse or alcohol abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liposomal prednisolone
Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
|
Liposomal prednisolone
Other Names:
|
Placebo Comparator: Placebo
Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
|
0.9% normal saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cephalic vein diameter
Time Frame: 6 weeks after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the diameter of the cephalic vein, six weeks after surgical creation of the radiocephalic shunt.
|
6 weeks after surgical creation of the radiocephalic shunt.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cephalic vein diameter
Time Frame: 3 months after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the diameter of the cephalic vein, three months after surgical creation of the radiocephalic shunt.
|
3 months after surgical creation of the radiocephalic shunt.
|
Radial artery diameter
Time Frame: 6 weeks after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the diameter of the radial artery, six weeks after surgical creation of the radiocephalic shunt.
|
6 weeks after surgical creation of the radiocephalic shunt.
|
Radial artery diameter
Time Frame: 3 months after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the diameter of the radial artery, three months after surgical creation of the radiocephalic shunt.
|
3 months after surgical creation of the radiocephalic shunt.
|
Radial artery flow.
Time Frame: 6 weeks after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the flow of the radial artery, six weeks after surgical creation of the radiocephalic shunt.
|
6 weeks after surgical creation of the radiocephalic shunt.
|
Radial artery flow.
Time Frame: 3 months after surgical creation of the radiocephalic shunt.
|
Echographic measurement of the flow of the radial artery, three months after surgical creation of the radiocephalic shunt.
|
3 months after surgical creation of the radiocephalic shunt.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Joris I Rotmans, MD PhD, Leiden University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
May 30, 2018
Study Completion (Actual)
May 30, 2018
Study Registration Dates
First Submitted
July 2, 2015
First Submitted That Met QC Criteria
July 8, 2015
First Posted (Estimate)
July 13, 2015
Study Record Updates
Last Update Posted (Actual)
September 18, 2018
Last Update Submitted That Met QC Criteria
September 17, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Pathological Conditions, Anatomical
- Fistula
- Neointima
- Vascular Remodeling
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- LIPMAT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Dialysis
-
Trakya UniversityCompleted
-
University of PittsburghNational Institute of Nursing Research (NINR); University of IowaCompleted
-
Inje UniversityKorea University Guro Hospital; Seoul National University; Hallym University... and other collaboratorsCompleted
-
Universidad Miguel Hernandez de ElcheCompleted
-
National University Hospital, SingaporeNational University of SingaporeUnknown
-
Far Eastern Memorial HospitalUnknown
-
Hamamatsu UniversityMaruyama Memorial General Hospital; Seirei Hamamatsu General Hospital; Iwata... and other collaboratorsTerminated
-
Hamamatsu UniversityMaruyama Memorial General Hospital; Seirei Hamamatsu General Hospital; Iwata... and other collaboratorsCompleted
-
The First Affiliated Hospital of Zhejiang Chinese...Not yet recruiting
-
Rabin Medical CenterNot yet recruitingRenal Dialysis
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States